BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31101803)

  • 1. Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies.
    Kumar S; Larson DR; Dispenzieri A; Therneau TM; Murray DL; Leif Bergsagel P; Kyle RA; Vincent Rajkumar S
    Blood Cancer J; 2019 May; 9(6):49. PubMed ID: 31101803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
    Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
    Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum free light chains in clinical laboratory diagnostics.
    Jenner E
    Clin Chim Acta; 2014 Jan; 427():15-20. PubMed ID: 23999048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance.
    Rajkumar SV; Kyle RA; Therneau TM; Clark RJ; Bradwell AR; Melton LJ; Larson DR; Plevak MF; Katzmann JA
    Br J Haematol; 2004 Nov; 127(3):308-10. PubMed ID: 15491291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement.
    Murray D; Kumar SK; Kyle RA; Dispenzieri A; Dasari S; Larson DR; Vachon C; Cerhan JR; Rajkumar SV
    Blood Cancer J; 2019 Dec; 9(12):102. PubMed ID: 31836698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study.
    Kaplan B; Golderman S; Aizenbud B; Esev K; Kukuy O; Leiba M; Livneh A; Ben-Zvi I
    Am J Hematol; 2014 Sep; 89(9):882-8. PubMed ID: 24866208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.
    Dispenzieri A; Katzmann JA; Kyle RA; Larson DR; Melton LJ; Colby CL; Therneau TM; Clark R; Kumar SK; Bradwell A; Fonseca R; Jelinek DF; Rajkumar SV
    Lancet; 2010 May; 375(9727):1721-8. PubMed ID: 20472173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.
    Rajkumar SV; Kyle RA; Therneau TM; Melton LJ; Bradwell AR; Clark RJ; Larson DR; Plevak MF; Dispenzieri A; Katzmann JA
    Blood; 2005 Aug; 106(3):812-7. PubMed ID: 15855274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical usefulness of serum free light chain measurement in monoclonal gammopathy].
    Shimazaki C; Murakami H; Sawamura M; Matsuda M; Kinoshita T; Hata H; Sugiura I; Tsushita K; Nagura E; Kosugi H; Itoh J; Shimizu K
    Rinsho Ketsueki; 2010 Apr; 51(4):245-52. PubMed ID: 20467220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany.
    Eisele L; Dürig J; Hüttmann A; Dührsen U; Assert R; Bokhof B; Erbel R; Mann K; Jöckel KH; Moebus S;
    Ann Hematol; 2012 Feb; 91(2):243-8. PubMed ID: 21789623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
    El-Khoury H; Lee DJ; Alberge JB; Redd R; Cea-Curry CJ; Perry J; Barr H; Murphy C; Sakrikar D; Barnidge D; Bustoros M; Leblebjian H; Cowan A; Davis MI; Amstutz J; Boehner CJ; Lightbody ED; Sklavenitis-Pistofidis R; Perkins MC; Harding S; Mo CC; Kapoor P; Mikhael J; Borrello IM; Fonseca R; Weiss ST; Karlson E; Trippa L; Rebbeck TR; Getz G; Marinac CR; Ghobrial IM
    Lancet Haematol; 2022 May; 9(5):e340-e349. PubMed ID: 35344689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
    Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
    Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases.
    Sabatino R; Perrone A; Cuomo M; Liotti S; Barchiesi V; Cantile M; Cavalcanti E
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Skin disorders associated with monoclonal gammopathies].
    Houtman CJ; Genders RE; von dem Borne PA; Vermeer MH
    Ned Tijdschr Geneeskd; 2014; 158():A6717. PubMed ID: 24780569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal gammopathy of undetermined significance.
    Kyle RA; Rajkumar SV
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):102-14. PubMed ID: 16231848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Light Chain Predominant Intact Immunoglobulin Monoclonal Gammopathy Disorders: Shorter Survival in Light Chain Predominant Multiple Myelomas.
    Singh G; Xu H
    Lab Med; 2021 Jul; 52(4):390-398. PubMed ID: 33180138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma.
    Rodríguez-García A; Linares M; Morales ML; Allain-Maillet S; Mennesson N; Sanchez R; Alonso R; Leivas A; Pérez-Rivilla A; Bigot-Corbel E; Hermouet S; Martínez-López J
    Front Immunol; 2021; 12():797209. PubMed ID: 35087522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monoclonal gammopathies of undetermined significance].
    Krizalkovicová V; Maisnar V; Pour L; Radocha J; Hájek R
    Klin Onkol; 2008; 21(4):160-4. PubMed ID: 19102222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.